Janice M. Reichert

Best Publications

• Development trends for human monoclonal antibody therapeutics

  Unknown

  1280
  Citations

• Bispecific antibodies: a mechanistic review of the pipeline.

  Aran F Labrijn;Maarten L Janmaat;Janice M Reichert;Paul W H I Parren

  1270
  Citations

• Monoclonal antibody successes in the clinic

  Unknown

  1022
  Citations

• Antibody–drug conjugates come of age in oncology

  Unknown

  753
  Citations

• Development trends for monoclonal antibody cancer therapeutics

  Unknown

  570
  Citations

• Antibodies to watch in 2019.

  Unknown

  555
  Citations

• Marketed therapeutic antibodies compendium

  Unknown

  525
  Citations

• Antibodies to watch in 2020.

  Unknown

  458
  Citations

• Recombinant protein therapeutics—success rates, market trends and values to 2010

  Unknown

  444
  Citations

• Development trends for therapeutic antibody fragments.

  Unknown

  408
  Citations

• Monoclonal antibodies as innovative therapeutics.

  Unknown

  357
  Citations

• The present and future of bispecific antibodies for cancer therapy.

  Unknown

  347
  Citations

• Antibody-based therapeutics to watch in 2011.

  Unknown

  343
  Citations

• Antibodies to watch in 2022

  Unknown

  329
  Citations

• Antibodies to watch in 2017

  Unknown

  317
  Citations

• Antibodies to watch in 2018

  Unknown

  313
  Citations

• Antibodies to watch in 2021.

  Unknown

  288
  Citations

• Antibodies to watch in 2023

  Unknown

  259
  Citations

• Monoclonal antibodies in the clinic.

  Unknown

  257
  Citations

• Marketing approval of mogamulizumab: A triumph for glyco-engineering

  Alain Beck;Janice M. Reichert

  232
  Citations